These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
168 related articles for article (PubMed ID: 34210681)
1. Standard-Dose Pembrolizumab Plus Alternate-Dose Ipilimumab in Advanced Melanoma: KEYNOTE-029 Cohort 1C, a Phase 2 Randomized Study of Two Dosing Schedules. Long GV; Robert C; Butler MO; Couture F; Carlino MS; O'Day S; Atkinson V; Cebon JS; Brown MP; Dalle S; Hill AG; Gibney GT; McCune S; Menzies AM; Niu C; Ibrahim N; Moreno BH; Diab A Clin Cancer Res; 2021 Oct; 27(19):5280-5288. PubMed ID: 34210681 [TBL] [Abstract][Full Text] [Related]
2. Pembrolizumab versus ipilimumab for advanced melanoma: final overall survival results of a multicentre, randomised, open-label phase 3 study (KEYNOTE-006). Schachter J; Ribas A; Long GV; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil C; Lotem M; Larkin J; Lorigan P; Neyns B; Blank C; Petrella TM; Hamid O; Zhou H; Ebbinghaus S; Ibrahim N; Robert C Lancet; 2017 Oct; 390(10105):1853-1862. PubMed ID: 28822576 [TBL] [Abstract][Full Text] [Related]
3. Pembrolizumab Plus Pegylated Interferon alfa-2b or Ipilimumab for Advanced Melanoma or Renal Cell Carcinoma: Dose-Finding Results from the Phase Ib KEYNOTE-029 Study. Atkins MB; Hodi FS; Thompson JA; McDermott DF; Hwu WJ; Lawrence DP; Dawson NA; Wong DJ; Bhatia S; James M; Jain L; Robey S; Shu X; Homet Moreno B; Perini RF; Choueiri TK; Ribas A Clin Cancer Res; 2018 Apr; 24(8):1805-1815. PubMed ID: 29358500 [No Abstract] [Full Text] [Related]
4. Long-term Follow-up of Standard-Dose Pembrolizumab Plus Reduced-Dose Ipilimumab in Patients with Advanced Melanoma: KEYNOTE-029 Part 1B. Carlino MS; Menzies AM; Atkinson V; Cebon JS; Jameson MB; Fitzharris BM; McNeil CM; Hill AG; Ribas A; Atkins MB; Thompson JA; Hwu WJ; Hodi FS; Guminski AD; Kefford R; Wu H; Ibrahim N; Homet Moreno B; Long GV Clin Cancer Res; 2020 Oct; 26(19):5086-5091. PubMed ID: 32605909 [TBL] [Abstract][Full Text] [Related]
5. Pembrolizumab versus ipilimumab in advanced melanoma (KEYNOTE-006): post-hoc 5-year results from an open-label, multicentre, randomised, controlled, phase 3 study. Robert C; Ribas A; Schachter J; Arance A; Grob JJ; Mortier L; Daud A; Carlino MS; McNeil CM; Lotem M; Larkin JMG; Lorigan P; Neyns B; Blank CU; Petrella TM; Hamid O; Su SC; Krepler C; Ibrahim N; Long GV Lancet Oncol; 2019 Sep; 20(9):1239-1251. PubMed ID: 31345627 [TBL] [Abstract][Full Text] [Related]
6. Standard-dose pembrolizumab in combination with reduced-dose ipilimumab for patients with advanced melanoma (KEYNOTE-029): an open-label, phase 1b trial. Long GV; Atkinson V; Cebon JS; Jameson MB; Fitzharris BM; McNeil CM; Hill AG; Ribas A; Atkins MB; Thompson JA; Hwu WJ; Hodi FS; Menzies AM; Guminski AD; Kefford R; Kong BY; Tamjid B; Srivastava A; Lomax AJ; Islam M; Shu X; Ebbinghaus S; Ibrahim N; Carlino MS Lancet Oncol; 2017 Sep; 18(9):1202-1210. PubMed ID: 28729151 [TBL] [Abstract][Full Text] [Related]